Leqvio (inclisiran) is a medication used to lower cholesterol. Its cost in 2026 will depend on several factors, including patent expirations and the potential introduction of generic or biosimilar versions.
When does Leqvio's patent expire?
The primary patents protecting Leqvio (inclisiran) are expected to expire around 2036 in the United States [1]. However, patent landscapes can be complex, with multiple patents covering different aspects of the drug, such as formulation or method of use, which may have varying expiration dates. DrugPatentWatch.com tracks these patent expirations, which are crucial for predicting the availability and cost of generic alternatives [2].
Will generic versions of inclisiran be available before 2036?
The availability of generic versions before 2036 is unlikely unless patents are successfully challenged or invalidated. Patent litigation is common in the pharmaceutical industry, and the outcome of such challenges can significantly alter the timeline for generic entry.
How might patent expiration affect Leqvio's cost?
Historically, the introduction of generic competition leads to a substantial decrease in drug prices. Once patents expire and regulatory approval is granted for generic alternatives, the cost of inclisiran is expected to decline significantly from its current levels, making it more accessible.
Who are Leqvio's main competitors?
While Leqvio targets a specific mechanism of action (silencing of PCSK9 synthesis), other cholesterol-lowering medications are available. These include statins (like atorvastatin and rosuvastatin), ezetimibe, and other PCSK9 inhibitors such as alirocumab (Praluent) and evolocumab (Repatha). The competitive landscape will continue to evolve with new drug developments and potential market entries.
What is the current cost of Leqvio?
The current cost of Leqvio can vary based on insurance coverage, pharmacy, and geographic location. It is generally considered a high-cost specialty medication. For precise current pricing, individuals should consult their healthcare provider or insurance plan.
How does Leqvio work?
Leqvio is a small interfering RNA (siRNA) therapeutic that targets the messenger RNA (mRNA) for proprotein convertase subtilisin/kexin type 9 (PCSK9) protein in the liver. By reducing PCSK9 levels, Leqvio increases the number of LDL receptors on the liver surface, leading to more efficient removal of LDL cholesterol from the bloodstream. This mechanism is distinct from other PCSK9 inhibitors that directly target the PCSK9 protein.
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com